{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T19:50:14Z","timestamp":1768852214354,"version":"3.49.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Tumefactive demyelination is a rare phenotypic subtype of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) and poses significant diagnostic challenges due to substantial clinical and radiological overlap with intracranial neoplasms and other demyelinating conditions. This mimicry frequently leads to misdiagnosis and subsequent inappropriate therapeutic interventions and delay in treatment, thereby increasing the risk of adverse clinical outcomes. We present the case of a 31-year-old male with a prior history of MOG-associated optic neuritis (ON) who developed acute-onset dizziness and gait instability evolving over five days. Brain magnetic resonance imaging (MRI) demonstrated an atypical mass-like lesion in the left cerebellar hemisphere with extension to the middle cerebellar peduncle. Serum testing showed MOG-IgG positivity at 1:100 titer (live cell-based assay) with negative AQP4-IgG. Following timely pulse corticosteroid therapy, the patient showed marked symptomatic improvement and received sequential maintenance of oral corticosteroid for six months. A follow-up MRI revealed complete resolution of abnormalities, and no recurrence was observed during the 21-month follow-up period. This case highlights the critical importance of including rare tumefactive MOGAD in the differential diagnosis of mass-like lesions, thereby avoiding the potential morbidity associated with misdiagnosis and delayed treatment. It also underscores the role of maintenance therapy in reducing relapses and preventing disability accumulation.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1729641","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T05:27:55Z","timestamp":1768800475000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cerebellar tumefactive demyelination in MOGAD: a case report on diagnostic challenges and immunotherapeutic strategy"],"prefix":"10.3389","volume":"16","author":[{"given":"XiaoDan","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JiaYue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DaWei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx276","article-title":"et al: Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1756286418762083","DOI":"10.1177\/1756286418762083","article-title":"Defining distinct features of anti-MOG antibody associated central nervous system demyelination","volume":"11","author":"Weber","year":"2018","journal-title":"Ther Adv neurological Disord"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1619807","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated cerebral cortical encephalitis: a case report highlighting diagnostic challenges and therapeutic implications","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000206820","article-title":"et al: tumefactive demyelination in MOG ab-associated disease, multiple sclerosis, and AQP-4-igG-positive neuromyelitis optica spectrum disorder","volume":"100","author":"Cacciaguerra","year":"2023","journal-title":"Neurology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.2811","article-title":"et al: time to treat first acute attack of myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"81","author":"Kwon","year":"2024","journal-title":"JAMA Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-304498","article-title":"Tumefactive demyelination: an approach to diagnosis and management","volume":"84","author":"Hardy","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)30043-6","article-title":"Atypical inflammatory demyelinating syndromes of the CNS","volume":"15","author":"Hardy","year":"2016","journal-title":"Lancet Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5332","DOI":"10.1038\/s41598-024-56016-2","article-title":"Author Correction: Tumefactive demyelinating lesions: a retrospective cohort study in Thailand","volume":"14","author":"Ongphichetmetha","year":"2024","journal-title":"Sci Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.7.1427","article-title":"Open-ring imaging sign: highly specific for atypical brain demyelination","volume":"54","author":"Masdeu","year":"2000","journal-title":"Neurology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182574f66","article-title":"Diffusion-weighted imaging characteristics of biopsy-proven demyelinating brain lesions","volume":"78","author":"Abou Zeid","year":"2012","journal-title":"Neurology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-325121","article-title":"et al: Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS","author":"Banks","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-09729-3","article-title":"Dynamic-susceptibility-contrast perfusion-weighted-imaging (DSC-PWI) in brain tumors: a brief up-to-date overview for clinical neuroradiologists","volume":"33","author":"Pons-Escoda","year":"2023","journal-title":"Eur Radiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-6111(02)00017-4","article-title":"Tumefactive demyelinating lesions by combined perfusion-weighted and diffusion weighted imaging","volume":"26","author":"Tsui","year":"2002","journal-title":"Comput Med Imaging Graph"},{"key":"B14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.msard.2018.08.025","article-title":"Proton magnetic resonance spectroscopy differentiates tumefactive demyelinating lesions from gliomas","volume":"26","author":"Ikeguchi","year":"2018","journal-title":"Multiple sclerosis related Disord"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2014.891046","article-title":"Impacts of MR spectroscopic imaging on glioma patient management","volume":"53","author":"Chronaiou","year":"2014","journal-title":"Acta Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbacli.2016.04.002","article-title":"Magnetic resonance spectroscopy - Revisiting the biochemical and molecular milieu of brain tumors","volume":"5","author":"Verma","year":"2016","journal-title":"BBA Clin"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1552-6569.2012.00760.x","article-title":"Structural and metabolic features of two different variants of multiple sclerosis: a PET\/MRI study","volume":"23","author":"Bolcaen","year":"2013","journal-title":"J Neuroimaging"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316880","article-title":"et al: Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"et al: Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"103693","DOI":"10.1016\/j.autrev.2024.103693","article-title":"MOGAD: A comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally","volume":"24","author":"Trewin","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005560","article-title":"et al: Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.3115","article-title":"Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin G-associated disorder","volume":"77","author":"Lopez-Chiriboga","year":"2020","journal-title":"JAMA Neurol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"et al: association of MOG-igG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-igG-associated disorders","volume":"75","author":"Lopez-Chiriboga","year":"2018","journal-title":"JAMA Neurol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"et al: serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-333463","article-title":"et al: Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse","volume":"95","author":"Trewin","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.42780","article-title":"et al: factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease in the United Kingdom","volume":"5","author":"Satukijchai","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B27","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"et al: Update on the use of immunoglobulin in human disease: A review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11940-019-0541-x","article-title":"Treatment approaches for MOG-ab-associated demyelination in children","volume":"21","author":"Hacohen","year":"2019","journal-title":"Curr Treat Options Neurol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.0489","article-title":"et al: association of maintenance intravenous immunoglobulin with prevention of relapse in adult myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"79","author":"Chen","year":"2022","journal-title":"JAMA Neurol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"103462","DOI":"10.1016\/j.msard.2021.103462","article-title":"Treatment of myelin oligodendrocyte glycoprotein antibody associated disease with subcutaneous immune globulin","volume":"57","author":"Sotirchos","year":"2022","journal-title":"Multiple sclerosis related Disord"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-013-9876-3","article-title":"Bioavailability of IgG administered by the subcutaneous route","volume":"33","author":"Berger","year":"2013","journal-title":"J Clin Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201260","article-title":"Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease","volume":"99","author":"Barreras","year":"2022","journal-title":"Neurology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"102696","DOI":"10.1016\/j.msard.2020.102696","article-title":"Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review","volume":"48","author":"Elsbernd","year":"2021","journal-title":"Multiple sclerosis related Disord"},{"key":"B34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/antib13020043","article-title":"Myelin oligodendrocyte glycoprotein-antibody associated disease: an updated review of the clinical spectrum, pathogenetic mechanisms and therapeutic management","volume":"13","author":"Gklinos","year":"2024","journal-title":"Antibodies (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1729641\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T05:27:55Z","timestamp":1768800475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1729641\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2025.1729641"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1729641","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"article-number":"1729641"}}